SS-31 (Elamipretide) — Cardiolipin-Targeted Mitochondrial Peptide

Discovery and origin

SS-31 — formally known as Elamipretide and alternatively as Bendavia or MTP-131 — is a synthetic tetrapeptide first described in 2004 by Professor Hazel Szeto and colleagues at Weill Cornell Medical College. The compound belongs to a class of compounds Szeto and co-investigator Peter Schiller developed through systematic structure-activity studies on opioid peptides, leading the team to coin the term "Szeto-Schiller peptides" (SS peptides) for the resulting series. SS-31 is the most extensively studied member of that series.

The foundational insight driving the SS peptide programme was the observation that certain aromatic-cationic sequences could concentrate spontaneously at the inner mitochondrial membrane (IMM) without requiring a mitochondria-targeting sequence, membrane potential, or active transport. Classical mitochondria-targeting strategies relied on a large, membrane-potential-dependent triphenylphosphonium (TPP) moiety that accumulated indiscriminately and caused membrane uncoupling at higher doses. Szeto's group instead exploited alternating cationic and aromatic residues to confer affinity for the anionic phospholipid environment of the IMM [PMID:15175329].

SS-31 carries the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt denotes the non-standard residue 2',6'-dimethyltyrosine. The exclusive use of D-amino acids — mirror-image versions of the natural L-forms — confers near-complete resistance to proteolytic degradation by endogenous peptidases, substantially extending the effective half-life relative to an L-configured analogue of identical sequence. The C-terminal amide (–NH2) further blocks exopeptidase attack. These structural choices produce a molecule with a molecular weight of approximately 639.8 Da that is readily water-soluble, membrane-permeable, and metabolically stable.

Mechanism of action

SS-31 operates through a mechanism that is fundamentally distinct from conventional antioxidant supplementation and from mitochondria-targeted antioxidants such as MitoQ. Rather than neutralising reactive oxygen species (ROS) after they are produced, SS-31 acts upstream by modifying the structural context in which the electron transport chain (ETC) operates.

Cardiolipin binding. Cardiolipin is an unusual phospholipid unique to the IMM, where it constitutes approximately fifteen to twenty percent of total lipid content. It plays an essential structural role: cardiolipin physically tethers the ETC complexes — particularly Complexes I, III, and IV — into efficient supercomplexes (respirasomes). Loss of cardiolipin integrity, which occurs in ageing, ischaemia-reperfusion injury, heart failure, and mitochondrial disease, causes supercomplex disassembly, electron leak, and consequently excess ROS generation. Birk et al. demonstrated that SS-31 binds directly to cardiolipin through electrostatic interaction of its cationic D-Arg and Lys residues with cardiolipin's two phosphate head groups, while the aromatic Dmt and Phe residues insert into the acyl-chain region [PMID:24529873]. This binding is non-covalent and reversible, and it does not alter cardiolipin's chemical structure.

Stabilisation of Complex IV (cytochrome c oxidase). One of the most functionally important consequences of cardiolipin binding by SS-31 is the preservation of the cardiolipin–cytochrome c interface at Complex IV. Cytochrome c shuttles electrons between Complex III and Complex IV, and its interaction with the IMM surface — mediated largely by cardiolipin — governs both efficient electron transfer and the likelihood of cytochrome c release into the cytoplasm (an early step in apoptosis). SS-31 binding stabilises the cardiolipin structure around cytochrome c, maintaining electron flux through Complex IV and reducing the probability of cytochrome c dissociation under stress conditions [PMID:24529873].

Selective suppression of mitochondrial ROS. By maintaining supercomplex integrity and reducing electron leak at Complexes I and III, SS-31 lowers mitochondrial superoxide production without acting as a direct radical scavenger. This selectivity is pharmacologically important: indiscriminate antioxidant supplementation can ablate the low-level ROS required for mitochondrial biogenesis signalling (via PGC-1α), redox-sensitive immune responses, and hypoxia sensing (via HIF-1α). SS-31 leaves these physiological ROS-dependent pathways intact while suppressing the pathological surplus generated under dysfunctional ETC conditions.

Preservation of ATP synthesis. Downstream of Complex IV stabilisation, SS-31 treatment in multiple models is associated with improved oxygen consumption rates, higher ATP:ADP ratios, and restored mitochondrial membrane potential. In cardiomyocytes subjected to ischaemia-reperfusion, SS-31 pre-treatment maintained Complex IV activity and reduced cytochrome c release, with corresponding improvements in cellular ATP levels and viability [PMID:25855803].

Researched applications

Primary mitochondrial myopathy (MMPOWER and MMPOWER-3). The most advanced clinical programme for SS-31 is in primary mitochondrial myopathy (PMM), a rare inherited disorder in which mutations in mitochondrial or nuclear DNA impair ETC function, causing profound muscle weakness, exercise intolerance, and multi-system involvement. Stealth BioTherapeutics conducted the MMPOWER trial and its successor MMPOWER-3, a Phase III randomised, double-blind, placebo-controlled study. Karaa et al. reported results from the MMPOWER programme showing that daily subcutaneous elamipretide produced significant improvements in the distance-to-fatigue walk test in a subset of patients with preserved baseline ambulation, alongside patient-reported improvements in fatigue and quality of life [PMID:29540588]. The full MMPOWER-3 dataset did not meet its primary endpoint on the total functional capacity composite score in the overall population, a result that was attributed partly to heterogeneity in the enrolled population and to difficulties in defining a sensitive composite endpoint for this rare disease. Regulatory discussions with the FDA around a potential accelerated pathway have continued.

Heart failure and the HEART-1 trial. Mitochondrial dysfunction is a recognised contributor to the energy deficit in chronic heart failure, where cardiomyocytes shift toward less efficient metabolic pathways and generate excess ROS. Daubert et al. published results from the HEART-1 Phase II trial of intravenous elamipretide in patients with heart failure with reduced ejection fraction (HFrEF). The trial demonstrated improved left ventricular end-systolic volume and a trend toward improved ejection fraction, with a favourable safety profile [PMID:28238614]. Sabbah et al. contributed preclinical data in canine models of heart failure confirming the mitochondrial mechanism: SS-31 treatment restored Complex I and IV activity in failing cardiomyocytes, reduced mitochondrial ROS, and improved bioenergetics at the cellular level [PMID:25855803].

Leber hereditary optic neuropathy (LHON) and ophthalmic applications. LHON is a maternally inherited mitochondrial disease caused by point mutations in the mitochondrial genome affecting Complex I subunits, leading to selective retinal ganglion cell death and acute vision loss. The retina has among the highest mitochondrial density of any tissue, making it particularly vulnerable to ETC dysfunction. SS-31 has been studied in LHON cell models and in rodent models of optic nerve crush injury, where it preserved retinal ganglion cell survival and axonal integrity. These findings motivated early-phase clinical investigation of elamipretide in LHON, with Stealth BioTherapeutics initiating trials for this indication alongside the PMM programme.

Ischaemia-reperfusion injury. A substantial body of preclinical work in cardiac, renal, and cerebral ischaemia-reperfusion models demonstrates that SS-31 administered prior to or immediately after reperfusion reduces infarct size, preserves organ function, and limits apoptotic cell death. The mechanism in these acute contexts is the rapid stabilisation of cardiolipin integrity and cytochrome c retention in the first minutes after reperfusion, a window during which mitochondria-targeted intervention has the greatest impact.

Dosing in research protocols

The dose range most commonly referenced in published preclinical and clinical research is five to ten milligrams per day, administered subcutaneously. The MMPOWER-3 trial used forty milligrams per day administered as a single subcutaneous injection, a dose level chosen based on earlier Phase II pharmacokinetic work establishing tolerability and target-organ exposure. In heart failure trials, intravenous infusion regimens have also been employed, with short infusion durations over four hours at doses in the range of zero point to 0.25 mg/kg.

In preclinical rodent models, SS-31 is most commonly dosed at three to ten mg/kg intraperitoneally or subcutaneously, once daily, for durations ranging from a single acute administration to twenty-eight days of chronic dosing. Human-equivalent extrapolation from rodent data using surface area conversion is not straightforward for mitochondria-targeted compounds because tissue distribution and IMM accumulation kinetics differ significantly between species.

It is emphasised that no established safe or effective dose exists for unapproved human use. All figures cited above are drawn from formal clinical trial protocols or published preclinical literature and are reported here for academic reference only.

Safety profile

The clinical trial safety database accumulated through the MMPOWER and HEART-1 programmes represents the most rigorous human safety data available for elamipretide. Injection-site reactions were the most frequently reported adverse events across both programmes: erythema, pain, and localised swelling at the subcutaneous injection site occurred in a substantial proportion of treated subjects but were predominantly mild-to-moderate in severity and did not lead to discontinuation in most cases. These reactions are consistent with the physicochemical properties of the peptide formulation and the subcutaneous route rather than with systemic pharmacological toxicity.

Headache was the next most commonly reported systemic adverse event, occurring at a slightly higher rate in actively treated arms than in placebo groups. Nausea and fatigue were reported at low frequencies and were generally transient. No clinically significant haematological, hepatic, or renal laboratory abnormalities were attributed to elamipretide in published safety analyses. Cardiac adverse events were not increased relative to placebo in the heart failure trial population, which carries an inherently elevated cardiac event rate at baseline.

Because SS-31 targets the IMM rather than acting as a systemic antioxidant, the theoretical risk of disrupting physiological ROS signalling appears low, and this has not emerged as a clinical concern in the trial data. The compound does not appear to affect mitochondrial membrane potential at therapeutic concentrations, in contrast to earlier TPP-conjugated mitochondria-targeted antioxidants.

UK regulatory status 2026

Elamipretide (SS-31) is not authorised as a medicinal product by the Medicines and Healthcare products Regulatory Agency (MHRA). It holds no Marketing Authorisation, no Specials licence, and no recognised veterinary approval in the United Kingdom. Its investigational status in the United States (under Stealth BioTherapeutics IND filings) does not confer any regulatory recognition in the UK or European Economic Area.

Under the Human Medicines Regulations 2012, supply or administration to humans for therapeutic or prophylactic purposes without a valid Marketing Authorisation or appropriate exemption is unlawful. Research-grade SS-31 may only be used within the UK in the context of in vitro laboratory research conducted under appropriate institutional governance, or within a formally approved clinical trial holding a valid Clinical Trial Authorisation (CTA) from the MHRA.

Researchers considering work with SS-31 should ensure that procurement is from a compliant supplier operating under Good Manufacturing Practice (GMP) or Good Laboratory Practice (GLP) standards as required by their institutional framework, and that all use is documented and falls within the scope of any applicable ethics approval.

Reconstitution and storage

SS-31 / Elamipretide is supplied as a lyophilised white powder and is readily soluble in sterile water for injection or bacteriostatic water (0.9% benzyl alcohol). Reconstitution to a concentration of one mg/mL in bacteriostatic water is the most common preparation used in published research protocols. The vial should be gently swirled — not shaken — to allow complete dissolution without inducing peptide aggregation; the resulting solution should be clear and colourless.

Reconstituted solution stored at two to eight degrees Celsius in a sealed, amber or foil-wrapped vial is considered stable for approximately fourteen days under standard laboratory conditions. For longer archiving, aliquoting into single-use volumes and storing at minus twenty degrees Celsius is standard practice; each aliquot should be thawed once at room temperature immediately before use and not refrozen. Repeated freeze-thaw cycles increase the risk of peptide degradation and should be avoided. Lyophilised powder, kept desiccated, protected from light, and stored below twenty-five degrees Celsius, retains integrity for twenty-four months from manufacture date or the period stated by the supplying laboratory.

Frequently asked research questions

What distinguishes SS-31 from MitoQ and other mitochondria-targeted antioxidants? MitoQ and similar TPP-conjugated compounds rely on membrane potential to accumulate in the matrix and function primarily as ROS scavengers. SS-31 does not depend on membrane potential — a key advantage when membrane potential is already compromised in disease states — and acts structurally at the cardiolipin–ETC interface rather than chemically neutralising superoxide after it is produced.

Why are D-amino acids used in SS-31? D-configured amino acids are not recognised by most mammalian proteases, which dramatically reduces peptide degradation in plasma and tissues and extends the biological half-life relative to an L-amino-acid analogue of identical sequence. This confers practical advantages for subcutaneous delivery without requiring formulation strategies such as PEGylation.

Did the MMPOWER-3 trial succeed? MMPOWER-3 did not meet its primary composite endpoint in the overall enrolled population [PMID:29540588]. Post-hoc analyses identified subgroups — particularly patients with higher baseline functional capacity — in which significant improvements in distance-to-fatigue were observed, and the compound's development has continued under a revised regulatory strategy.

Is SS-31 the same compound as Bendavia? Yes. Bendavia was the trade name used by Stealth BioTherapeutics during earlier phases of clinical development; MTP-131 was an alternative research designation. All three names — SS-31, Elamipretide, and Bendavia — refer to the same D-Arg-Dmt-Lys-Phe-NH2 tetrapeptide.

Can SS-31 be combined with other mitochondrial peptides in research? Humanin and MOTS-c are mitochondria-derived peptides that act through cytoplasmic and nuclear signalling (IGF-1R, AMPK) rather than at the IMM structural level. Their mechanisms are non-overlapping with SS-31's cardiolipin-binding action, which has motivated investigation of combinatorial approaches in preclinical models. Formal interaction or combination studies in humans have not been reported.

---

SS-31 appears in the following research stacks on this site: SS-31 + Humanin Mitochondrial Stack.

Source research-grade SS-31

SS-31 (Elamipretide) — Cardiolipin-Targeted Mitochondrial Peptide is sold for laboratory and in vitro research use only. UK regulatory status: Phase III clinical-trial pipeline (Stealth BioTherapeutics) for primary mitochondrial myopathy and other indications. Not FDA/EMA/MHRA-approved as of May 2026. Research-grade material remains research-only..

Source on PeptideBarn.co.ukFull monograph on PeptideAuthority.co.uk